Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma

Fig. 1

CD38 and CD138 expression in multiple myeloma cell lines and identification of antagonist peptides. a Crystal structure of CD38 (blue) binding to the heavy chain of SAR650984-Fab (green), from which CD38pep is derived (PDB# 4CMH). CD38pep replicates the H3 loop of SAR650984-Fab. b, c Structures of CD38pep (b) and CD138pep (c), antagonist peptides for CD38 and CD138 respectively. d Screening of multiple myeloma cell lines for the presence of CD38 and CD138 receptors using FITC-labeled as determined by flow cytometry. e Cellular binding assays using fluorescein-labeled CD38pep and CD138pep. Binding was detected by flow cytometry. Fluorescence of cells incubated without peptides was minimal and subtracted from the presented data. All experiments were done in triplicate. Data represent means (± s.d.)

Back to article page